Cellectar Biosciences, Inc. CLRB
1.22 USD -0.06 (-4.69%)
At closeNov 10, 2026, 4:00 PM EST
1.22 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
1.22 Day range 1.32
1.11 52-week range 4.70
- YTD
- -58.64%
- 1 year
- -65.54%
News
benzinga.com Cellectar Biosciences Q3 2026 Earnings Call Transcript Cellectar Biosciences (NASDAQ:CLRB) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
globenewswire.com Cellectar Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy for iopofosine I 131 in Waldenström…
benzinga.com Cellectar Biosciences Q3 EPS $(0.46) Beats $(0.56) Estimate Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.56) by 17.86 percent. This is a 67.38 percent increase over losses…
benzinga.com Cellectar Biosciences To Present Three Posters For Its Radiopharmaceutical Candidate At American Society Of Hematology Annual Meeting Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters…
globenewswire.com Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3…
benzinga.com Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131 Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million. Option Care Health (NASDAQ:OPCH) stock…
benzinga.com Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
benzinga.com Cellectar Biosciences Q2 2026 Earnings Call Transcript On Thursday, Cellectar Biosciences (NASDAQ:CLRB) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by…
benzinga.com Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.48) by 18.75 percent. This is a 83.19 percent increase over…- benzinga.com Cellectar Biosciences Announces Publication Of Results From Phase 1 Dose-Escalation Study Evaluating Iopofosine I 131 In Combination With Low-Dose Dexamethasone In 31 Patients With Heavily Pretreated R/R MM Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple MyelomaPublication Supports Continued Development of Iopofosine I 131 as a Novel…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com Cellectar Biosciences To Highlight Efficacy Results From Phase 2 CLOVER WaM Clinical Trial Of Iopofosine I 131 To Treat r/r WM At 2026 ASCO Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi TherapyPlans to Initiate Phase 3…
- benzinga.com Cellectar Biosciences Files Prospectus For Offering Of Up To 51.2M Shares Of Common Stock By Selling Stockholders https://www.sec.gov/Archives/edgar/data/1279704/000110465926063918/tm2614975d1_s1.htm
- benzinga.com Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10 Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.
- benzinga.com Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com Cellectar Biosciences Q1 EPS $(1.33) Beats $(1.89) Estimate. Cash And Equivalents $8.35M Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.33) per share which beat the analyst consensus estimate of $(1.89) by 29.26 percent. This is a 69.07 percent increase over losses…
benzinga.com Crude Oil Down 4%; PayPal Shares Fall After Q1 Results US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2.1%, financials down 0.2%. PayPal shares fall 9%.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
benzinga.com Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 earnings beat expectations. Asian markets close lower.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Market-Moving news for May 5th PINS: 19% | Pinterest shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates. CLRB: 145% | Cellectar Biosciences…- benzinga.com Earnings Scheduled For March 4, 2026
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - benzinga.com Earnings Scheduled For November 13, 2025
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Earnings Scheduled For August 14, 2025 - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings - benzinga.com Earnings Scheduled For May 13, 2025
- benzinga.com Earnings Scheduled For March 13, 2025
- benzinga.com Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
- benzinga.com Earnings Scheduled For November 18, 2024
benzinga.com Gold Moves Higher; Coca-Cola Increases FY24 Forecast - benzinga.com Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com Crude Oil Down 2%; GE Aerospace Earnings Top Views
- benzinga.com Earnings Scheduled For March 27, 2024 Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
- benzinga.com Earnings Scheduled For November 2, 2023 Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
- benzinga.com Why Energy Stocks Traded Higher; Here Are 61 Biggest Movers From Yesterday Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) jumped 150.4% to close at $1.59 on Monday after declining 8% on Friday.
- benzinga.com Why Is Infrastructure and Energy Alternatives Higher By Around 29%? 37 Stocks Moving In Monday's Mid-Day Session Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 104% to $1.3263 after the company announced that primary endpoint was met in study for its treatment of allergic rhinitis.
- benzinga.com Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday Gainers Pagaya Technologies Ltd. (NASDAQ: PGY) shares climbed 129.6% to close at $6.20 on Wednesday. Pagaya Technologies is expected to announce its Q2 earnings on August 16, 2022.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.